You are here: Industry Insights > Dry Eye Disease

News List

Boost for Dry Eye Disease Treatment As FDA Approves Generic Drug SHEM OIRERE
February 28, 2022
The Federal Drugs Agency (FDA) has approved the Abbreviated New Drug Application for the making of Cyclo-sporine Ophthalmic Emulsion 0.05%, the first generic version of AbbVie Inc's Re-stasis. (1)
The Pharmaceutical Company Licenses in Two New Drugs for Dry Eye Disease with over 200 Million US Dollars PharmaSources/Yefenghong
August 25, 2021
On August 5, Oyster Point Pharma, Inc. revealed on its official website that it has reached a cooperation agreement with Ji Xing Pharmaceuticals, which will develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients.
Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease prnasia
December 22, 2021
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial...
Palatin Announces Positive Results from PL9643 Study in Patients with Dry Eye Disease americanpharmaceuticalreview
January 05, 2021
Palatin Technologies announced positive results in its Phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population ...
Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease pharmaceutical-business-review
October 30, 2020
Kala Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
Neuroptika Completes Enrollment of Phase 2 Clinical Trial for Dry Eye Disease americanpharmaceuticalreview
August 20, 2020
Neuroptika announced completion of enrollment in a Phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease.
Palatin Announces Enrollment Reinitiation of PL9643 Study for Dry Eye Disease americanpharmaceuticalreview
July 17, 2020
Palatin Technologies announced reinitiation of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease (DED).
Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry e pharmaceutical-business-review
May 15, 2020
Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial pharmaceutical-business-review
March 12, 2020
Kala Pharmaceuticals said that its dry eye disease candidate KPI-121 0.25% has delivered positive results in a phase 3 trial called STRIDE 3.
Palatin Announces First Patient Enrolled in Dry Eye Disease Trial with PL9643 americanpharmaceuticalreview
March 09, 2020
Palatin Technologies has enrolled the first patient in a Phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED).

Previous page 1 2 Next page